Summary
Bromocriptine, a D2 receptor agonist, was administered intravenously (1 mg/kg) to anesthetized rats. Microdialysis probes were implanted in the pituitary and the striatum, known sites of D2 agonist action. Bromocriptine and its metabolites were monitored in plasma and tissue dialysates for 4 h. Drug analyses were performed using two different enzyme immunoassays specific for untransformed bromocriptine or a pool of parent drug plus hydroxylated metabolites. The metabolites/parent drug ratio for areas under the curve was 5.5. in plasma and 1 in the pituitary. No metabolites could be detected in the striatum. Bromocriptine penetration was at least 10-fold greater in the pituitary than in the striatum. The kinetics of bromocriptine in the pituitary and striatum did not parallel those in plasma, indicating that the prolonged action of bromocriptine reported by other authors may be due to slow dissociation from receptors.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Thorner M.O., Schran H.F., Evans W.S., Rogol A.D., Morris J.L., McLeod R.M. (1980): A broad spectrum of prolactin suppression by bromocriptine in hyperprolactinemic women: a study of serum prolactin and bromocriptine levels after acute and chronic administration of bromocriptine. J. Clin. Endocrinol. Metab., 50, 1026–1032.
Coleman R.J. (1992): Current drug therapy for Parkinson’s disease. A review. Drug Agings, 2, 112–124.
Kopin I.J. (1993): The pharmacology of Parkinson’s disease therapy: an update. Annu. Rev. Pharmacol. Toxicol., 32, 467–495.
Katz E., Weiss B.E., Hassell A., Schran H.F., Adashi E.Y. (1991) Increased circulating levels of bromocriptine after vaginal compared with oral administration. Fertil. Steril., 55, 882–884.
Jackson D.M., Jenkins O.F., Ross S.B. (1988): The motor effect of bromocriptine — a review. Psychopharmacology, 95, 433–446.
Markey S.P., Colburn R.W., Kopin I.J., Aamodt R.L. (1979): Distribution and excretion in the rat and monkey of [82Br]-bromocriptine. J. Pharmacol. Exp. Ther., 211, 31–35.
Phelan D.G., Greig N.H., Rapoport S.I., Soncrant T.T. (1990): High-performance liquid chromatographic assay of bromo-criptine in rat plasma and brain. J. Chromatogr., 533, 264–270.
Westerink B.H.C., Damsma G., Rollema H., De Vries J.B., Horn A.S. (1987): Scope and limitations of in vivo brain dialysis: a comparison of its application to various neurotransmitter systems. Life Sci., 41, 1763–1776.
Benveniste H. (1989): Brain microdialysis. J. Neurochem., 52, 1667–1679.
Lonnroth P., Smith U. (1990): Microdialysis — a novel technique for clinical investigations. J. Intern. Med., 227, 295–300.
Stahle L. (1993): Microdialysis in pharmacokinetics. Eur. J. Drug. Metab. Pharmacokinet., 18, 89–96.
Barjavel M., Sandouk P., Plotkine M., Schermann J.M. (1994): Morphine and morphine metabolites’ kinetics in the rat brain as assessed by transcortical, microdialysis. Life Sci., 55, 1301–1308.
Sato Y., Shibanoki S., Sugahara M., Ishikawa K. (1994): Measurement and pharmacokinetic analysis of imipramine and its metabolite by brain microdialysis. J. Pharmacol., 112, 625–629.
Schaefer F., Daschner M., Veldhuis J.D., Oh J., Qadri F., Scharer K. (1994): In vivo alterations in the gonadotropin-releasing hormone pulse generator and the secretion and clearance of luteinizing hormone in the uremic castrate rat. Neuroendocrinology, 59, 285–296.
Paxinos G., Watson C. (1982). The rat brain. In: Paxinos G., Watson C. (eds) Stereotaxic Coordinates. New York: Academic Press. p. 7–12.
Rosenthaler J., Munzer H., Vosges V. (1983): Immunoassay of bromocriptine and specificity of antibody. In: Reid E., Leppard J.P. (eds) Drug Metabolite Isolation and Determination. New York: Plenum, 215–223.
Valente D., Ezan E., Créminon C., Delaforge M. et al. (1996): Enzyme immunoassays for bromocriptine and its metabolites. J. Immunoassay, 17(4), 227–320.
Maurer G., Schreier E., Delaborde S., Loosli H.R., Nufer R., Shukla A.P. (1982): Fate and disposition of bromocriptine in animals and man. I: Structure elucidation of the metabolites. Eur. J. Drug. Metab. Pharmacokinet., 7, 281–292.
Maurer G., Schreier E., Delaborde S., Nufer R., Shukla A.P. (1983): Fate and disposition of bromocriptine in animals and man. II: Absorption, elimination and metabolism. Eur. J. Drug Metab. Pharmacokinet., 8, 51–62.
Pan H.T., Menacherry S., Justice J.B. (1991): Differences in the pharmacokinetics of cocaine in naive and cocaine-experienced rats. J. Neurochem., 56, 1299–1306.
Woof P.D. (1981): Resumption of prolactin secretion after dopaminergic inhibition: differential effects of dopamine and its agonists. Am. J. Physiol., 240, 700–704.
Montrastruc J.L., Rascol O., Senard J.M. Rascol A. (1994): A randomised controlled study comparing bromocriptine to which levodopa was later added, with levadopa alone in previously untreated patients with Parkinson’s disease: a five year follow up. J. Neurol. Neurosurg. Psychiatry, 57, 1034–1038.
Reavill C., Jenner P., Marsden C.D. (1980): Metabolite involvement in bromocriptine induced circling behaviour in rodents. J. Pharm. Pharmacol. 32, 278–284.
Keller H.H., Da Prada M. (1979): Central dopamine agonistic activity and microsomal biotransformation of lisuride, lergotrile and bromocriptine. Life Sci., 24, 1211–1222.
Gonzalez-Lima F., Hart W.T., Rivera-Quinones C. (1987): Metabolite involvement in the behavioral effects in cats. Eur. J. Pharmacol. 141, 109–115.
Schran H.F., Tse F.L.S., Bhuta S.I. (1985): Pharmacokinetics and pharmacodynamics of bromocriptine in the rat. Biopharm. Drug. Dispos., 6, 301–311.
Stahle L., Segersvard S., Ungerstedt U. (1991): A comparison between three methods for estimation of extracellular concentrations of exogenous and endogenous compounds by microdialysis. J. Pharmacol. Methods, 25, 41–52.
Larsson C.I. (1991): The use of an ‘internal standard’ for control of the recovery in microdialysis. Life Sci., 49, PL73-PL78.
Menacherry S., Hubert W., Justice J.B. (1992): In vivo calibration of microdialysis probes for exogenous compounds. Anal. Chem., 64, 577–583.
Eisenberg E.J., Conzentino P., Eickhoff W.M., Cundy K.C. (1993): Pharmacokinetic measurements of drugs in lung epithelial linging fluid by microdialysis: aminoglycoside antibiotics in rat bronchi. J. Pharmacol. Methods, 29, 93–98.
Meredith J.M., Levine J.E. (1992): Effects of castration on LH-RH patterns in intrahypophysial microdialysates. Brain Res., 571, 181–188.
Leleu D., Sarre S., Ebinger G., Michotte Y. (1993): J. Pharm. Biomed. Anal., 11, 577–585.
Deboer P., Abercombie E.D., Heeringa M., Westerlink B.H. (1993): Differential effect of systemic administration of bromocriptine and L-DOPA on the release of acetylcholine from striatum of intact and 6-OHDA-treated rats. Brain Res., 608, 198–203.
Brannan T., Martinez-Tica J., Di-Rocco A., Yarh M.D. (1993): Low and high dose bromocriptine have different effects on striatal dopamine release: an in vivo study. J. Neural. Transm., 6, 81–87.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Granveau-Renouf, S., Valente, D., Durocher, A. et al. Microdialysis study of bromocriptine and its metabolites in rat pituitary and striatum. Eur. J. Drug Metab. Pharmacokinet. 25, 79–84 (2000). https://doi.org/10.1007/BF03190071
Received:
Issue Date:
DOI: https://doi.org/10.1007/BF03190071